BMS finally gets FDA OK for liso-cel, sets $410k launch priceBristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US Share XBMS finally gets FDA OK for liso-cel, sets $410k launch pricehttps://pharmaphorum.com/news/bms-finally-gets-fda-ok-for-liso-cel-sets-410k-launch-price/
ASH: Lilly builds case for its BTK drug LOXO-305 in lymphomaEli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has Share XASH: Lilly builds case for its BTK drug LOXO-305 in lymphomahttps://pharmaphorum.com/news/ash-lilly-builds-case-for-its-btk-drug-loxo-305-in-lymphoma/
FDA sets May date for verdict on ADC’s lymphoma drug LoncaADC Therapeutics could claim its first product approval in the US next May, after the FDA started a Share XFDA sets May date for verdict on ADC’s lymphoma drug Loncahttps://pharmaphorum.com/news/fda-sets-may-date-for-verdict-on-adcs-lymphoma-drug-lonca/
Merck & Co buys cancer biotech VelosBio for $2.75bnMerck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion Share XMerck & Co buys cancer biotech VelosBio for $2.75bnhttps://pharmaphorum.com/news/merck-co-buys-cancer-biotech-velosbio-for-2-75bn/
NICE recommends regular NHS funding for Roche’s lymphoma drug PolivyNICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning Share XNICE recommends regular NHS funding for Roche’s lymphoma drug Polivyhttps://pharmaphorum.com/news/nice-recommends-regular-nhs-funding-for-roches-lymphoma-drug-polivy/
FDA to decide on TG Therapeutics’ lymphoma drug early next yearThe FDA has accepted TG Therapeutics’ filing for its lymphoma drug umbralisib, which if approved could compete against Share XFDA to decide on TG Therapeutics’ lymphoma drug early next yearhttps://pharmaphorum.com/news/fda-to-decide-on-tg-therapeutics-lymphoma-drug-early-next-year/
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibodyIncyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope Share XIncyte/Morphosys take on CAR-Ts with $198,000 per year antibodyhttps://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/
Scopus Bio preps trials of gene-silencing immuno-oncology drugScopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start Share XScopus Bio preps trials of gene-silencing immuno-oncology drughttps://pharmaphorum.com/news/scopus-bio-preps-trials-of-gene-silencing-immuno-oncology-drug/
AbbVie forges $3.9 billion oncology alliance with GenmabAbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed Share XAbbVie forges $3.9 billion oncology alliance with Genmabhttps://pharmaphorum.com/news/abbvie-forges-3-9-billion-oncology-alliance-with-genmab/
